Trials / Completed
CompletedNCT03854019
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- The University of Texas Health Science Center, Houston · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess efficacy and safety of dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) in patients with irritability due to Huntington's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) | DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days. |
| DRUG | Placebo | Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days. |
Timeline
- Start date
- 2019-08-05
- Primary completion
- 2022-11-11
- Completion
- 2022-11-11
- First posted
- 2019-02-26
- Last updated
- 2024-01-05
- Results posted
- 2024-01-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03854019. Inclusion in this directory is not an endorsement.